Merkert Center 201
Telephone: 617-552-1778
Email: abhishek.chatterjee@bc.edu
ORCID
Combining directed evolution and chemical approaches to engineer biology for developing next-generation biotherapeutics and novel tools to probe complex biological questions.
The Chatterjee group takes an interdisciplinary approach to engineer biology with the ultimate goal of developing new technologies to probe complex biological questions, and to create novel biotherapeutics that target challenging human diseases. A particular focus of the group is the development of technology for site-directed incorporation of noncanonical amino acids (ncAAs) with enabling chemistries into proteins expressed in living cells. We are using this technology for: 1) The development of new bioorthogonal conjugation reactions, especially ones that are compatible with existing bioconjugation chemistries to enable site-specific protein labeling with multiple distinct entities; 2) The development of next-generation biotherapeutics, such as therapeutic protein conjugates, as well as precisely modified adeno-associated virus vectors for human gene therapy; 3) Elucidating the roles of various post-translational modifications of mammalian proteins; 4) Versatile analysis of newly synthesized proteins in living cells. In order to facilitate these applications, we have: 1) Developed new aminoacyl-tRNA synthetase/tRNA platforms that enable site-specific incorporation of previously inaccessible structural classes of ncAAs, 2) Combined these platforms to enable site-specific incorporation of multiple distinct ncAAs into proteins, 3) Developed optimized delivery strategies for introducing the ncAA incorporation machinery in a broad range of mammalian cells, and 4) Developed a novel mammalian cell-based directed evolution platform to improve the performance of the ncAA incorporation machinery.
2024 Bioconjugate Chemistry Young Investigator Award
2022 Allen Distinguished Investigator Award
2018 Camille Dreyfus Teacher-Scholar Award
2018 Scialog® Fellowship (Research Corporation and the Moore Foundation)
2013 Smith Family Award for Excellence in Biomedical Sciences